ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Identification and Validation of Three-Gene Signature in Lung Squamous Cell Carcinoma by Integrated Transcriptome and Methylation Analysis

Li, Guanghua; Wu, Libo; Yu, Jiaxing; Zhai, Siyang; Deng, Hailong; Wang, Qiushi*哈尔滨医科大学; 海南医学院
Journal of Oncology2022-9-23DOI: 10.1155/2022/9688040
1被引5阅读
引用收藏
分享

摘要

Since DNA methylation (DNAm) is associated with the carcinogenesis of various cancers, this study aimed to explore potential DNAm prognostic signatures of lung squamous cell carcinoma (LUSC). First, transcriptomic and methylation profiles of LUSC were obtained from The Cancer Genome Atlas database (TCGA). DNAm-related genes were screened by integrating DNAm and transcriptome profiles via MethylMix package. Subsequently, a prognostic signature was conducted with the least absolute shrinkage and selector operation (LASSO) Cox analysis. This signature combined with the clinicopathological parameters was then utilized to construct a prognostic nomogram via the rms package. A signature based on three DNAm-related genes claudin 1 (CLDN1), ATP-binding cassette subfamily C member 5 (ABCC5), and cystatin A (CSTA) that were hypomethylated and upregulated in LUSC was constructed. Univariate and multivariate Cox regression analysis suggested that this signature, combined with age and TNM.N stage, was significantly correlated with survival rate. Time-dependent receiver operating characteristics and calibration curves suggested the nomogram constructed with age and TNM.N stage variables could accurately evaluate the 3- and 5-year outcome of LUSC. Finally, the average mRNA and protein expression levels of CLDN1, ABCC5, and CSTA in LUSC were verified to be significantly higher than those in paracancerous tissues. Moreover, silencing CLDN1, ABCC5, and CSTA expressions could significantly reduce the carcinogenesis of the A549 cell line. The DNAm-driven prognostic signature consists of CLDN1, ABCC5, and CSTA incorporated with age and TNM. N stage could facilitate the prediction outcome of LUSC.

学科与关键词

关键词
DNA METHYLATIONUP-REGULATIONCANCERRESISTANCEGENEEXPRESSIONABCC5
相关
加载中…
  • Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma
    Lee, Nan; Xia, Xuelian; Meng, Hui; Zhu, Weiliang; Wang, Xiankai; Zhang, Tianyuan; Zhang, Chanyuan; Zhang, Jian*; Luo, Peng*Cancer Biomarkers, 2021, 30(1): 63-73.被引 4
  • Development and Validation of Epigenetic Signature Predict Survival for Patients with Laryngeal Squamous Cell Carcinoma
    Cui, Jie; Wang, Liping; Zhong, Waisheng; Chen, Zhen; Chen, Jie*; Yang, Hong*; Liu, Genglong*DNA and Cell Biology, 2021, 40(2): 247-264.被引 15
  • Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma
    Li Xiu Shen; Nie Ke Chao; Zheng Zhi Hua; Zhou Rui Sheng; Huang Yu Sheng; Ye Zeng Jie; He Fan; Tang YingBMC Cancer, 2021, 21(1).
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Oncology
发表日期
2022-09-23
卷期
第 2022 卷
页码
9688040
DOI
10.1155/2022/9688040
期刊等级
4区
成果收录
SCIE
资助标注
Natural Science Foundation of Heilongjiang Province; [H2015004]

作者

  • L

    Li, Guanghua (第一作者)

    2 · harbin med univ

  • W

    Wu, Libo

    2 · hainan med coll

查看全部 6 位作者收起作者
  • Y

    Yu, Jiaxing

    2 · harbin med univ

  • Z

    Zhai, Siyang

    2 · harbin med univ

  • D

    Deng, Hailong

  • W

    Wang, Qiushi (通讯)

    2 · harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417